Home > Insider Trading > Filing (0001104659-10-028563)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
873303	Avi Biopharma Inc	AVII	Pharmaceutical Preparations (2834)	930797222

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1223756	R Anthony Chase	3450 Monte Villa Parkway, Suite 101 Bothell WA 98021		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2010-05-12	96,000	$1.35	265,360	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Common Stock Purchase Warrants	$1.78	2010-02-25	2014-08-25	140,000	350,000	Direct
Common Stock	Non-Qualified Stock Option (right to buy)	$1.24	2011-04-20	2020-04-20	60,000	60,000	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2014-08-25	140,000	350,000	Direct
2020-04-20	60,000	60,000	Direct

Footnotes

Mr. Chase holds 350,000 warrants to purchase common stock. Each warrant can be exercised to purchase 4/10 (or 0.4) of a share of common stock. Thus, Mr. Chase's 350,000 warrants are exercisable to purchase 140,000 shares of common stock at $1.78 per share.
Such options shall have a four-year vesting period commencing on the Grant Date, 1/4th of the shares vest and become exercisable on the earlier of one year after the Grant Date or the commencement of the next succeeding annual meeting of shareholders; 1/4th of the shares vest and become exercisable on the earlier of two years after the Grant Date or the commencement of the next succeeding annual meeting of shareholders, 1/4th of the shares vest and become exercisable on the earlier of three years after the Grant Date or the commencement of the next succeeding annual meeting of shareholders and 1/4th of the shares vest and become exercisable on the earlier of four years after the Grant Date or the commencement of the next succeeding annual meeting of shareholders.